Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients
Public ClinicalTrials.gov record NCT03610724. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study was to assess the efficacy and safety of tisagenlecleucel in pediatric, adolescent and young adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) including Burkitt Lymphoma and Burkitt Leukemia. For pediatric patients who have r/r B-NHL including Burkitt Lymphoma and Burkitt Leukemia, survival rates are dismal, only \~20-50% subjects are alive at 2 years with overall response rate (ORR) of 20-30% after conventional salvage chemotherapy.
Study identification
- NCT ID
- NCT03610724
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Interventions
- Tisagenlecleucel Biological
- lymphodepleting chemotherapy Drug
- Bridging Therapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- Up to 25 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 14, 2019
- Primary completion
- Jul 26, 2021
- Completion
- Apr 25, 2023
- Last update posted
- Jun 19, 2024
2019 – 2023
United States locations
- U.S. sites
- 8
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| UCSF Medical Center | San Francisco | California | 94143 | — |
| Johns Hopkins Oncology Center ORA | Baltimore | Maryland | 21231 | — |
| Dana Farber Cancer Institute Dept.of DFCI | Boston | Massachusetts | 02215 | — |
| Memorial Sloan Kettering Cancer Center MSKCC (8) | New York | New York | 10065 | — |
| Cinn Children Hosp Medical Center | Cincinnati | Ohio | 45229-3039 | — |
| The Childrens Hospital of Philadelphia Drug Shipment | Philadelphia | Pennsylvania | 19104 | — |
| University of Texas Southwestern Medical Center . | Dallas | Texas | 75235 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
Recently updated Non-Hodgkin Lymphoma trials
Other public records listing Non-Hodgkin Lymphoma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07763210: Lazarus: IT Therapy for ICANS Not yet recruiting
- NCT07750886: Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Recruiting
- NCT06013423: Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Recruiting
- NCT06580002: Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial Recruiting
- NCT07679919: BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies Not yet recruiting
- NCT07652580: Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03610724, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 19, 2024 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03610724 live on ClinicalTrials.gov.